HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Nalidixic Acid

Subscribe to New Research on Nalidixic Acid

A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE.

Also Known As:

Nalidixate Sodium; Nevigramon; Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Acid, Nalidixic; Sodium, Nalidixate; Nalidixin; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-

Networked: 451 relevant articles (31 outcomes, 39 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Dolecek, Christiane: 3 articles (01/2013 - 01/2008)
2.	Ryzhko, I V: 3 articles (01/2010 - 01/2000)
3.	Kapil, Arti: 3 articles (08/2008 - 02/2002)
4.	Mani, Kavaratty Raju: 2 articles (08/2013 - 01/2009)
5.	Sharma, Anshu: 2 articles (08/2013 - 01/2009)
6.	Kumar, Yashwant: 2 articles (08/2013 - 01/2009)
7.	Farrar, Jeremy: 2 articles (01/2013 - 01/2008)
8.	Wolbers, Marcel: 2 articles (01/2013 - 08/2011)
9.	Baker, Stephen: 2 articles (01/2013 - 08/2011)
10.	Basnyat, Buddha: 2 articles (01/2013 - 01/2008)

Related Diseases

1.	Bacillary Dysentery (Shigellosis) 11/01/2004 - "As a consequence, should antimicrobial therapy be indicated, the efficacy of nalidixic acid as the preferred treatment for children with bacillary dysentery has been jeopardised." 11/01/1988 - "I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis." 08/01/2009 - "Nalidixic acid has been one of the most common agents used for the treatment of shigellosis. " 12/01/2002 - "Reported here is a retrospective molecular analysis of the isolates recovered from the first outbreak of nalidixic acid (NA)-resistant Shigella sonnei shigellosis to occur in Israel. " 12/01/2002 - "Retrospective analysis of the first clonal outbreak of nalidixic acid-resistant Shigella sonnei shigellosis in Israel."
2.	Infection 10/01/1973 - "In vivo, doses required for successful therapy of experimental mouse infections were comparable to those for nalidixic acid. " 04/01/1988 - "Nalidixic acid--though effective in in vitro tests of bacterial susceptibility--thus was found to be of little or no value as prophylaxis against Gram-negative infection. " 01/01/2009 - "The study may be helpful in revising treatment strategies for the infections caused by nalidixic acid resistant Salmonella Typhi in the country." 11/01/1965 - "[A bacteriologic study on non-specific infections of the urinary tracts and clinical evaluation of nalidixic acid]." 10/01/1964 - "[STUDY OF THE ACTION OF NALIDIXIC ACID IN URINARY INFECTIONS]."
3.	Typhoid Fever (Typhoid) 08/01/2009 - "The purpose of this study was to examine the rate and clinical consequences of nalidixic acid-resistant (NAR) isolates in travellers with enteric fever presenting to a hospital in a developed country. " 01/01/2013 - "Of the 218 patients with culture confirmed enteric fever, 170 patients were infected with nalidixic acid-resistant isolates. " 08/01/2009 - "Increasing rates and clinical consequences of nalidixic acid-resistant isolates causing enteric fever in returned travellers: an 18-year experience." 01/01/2008 - "To find out the frequency of low-level quinolone-resistance in Multi-Drug Resistant (MDR) typhoid using nalidixic acid screening disc. " 01/01/2006 - "Screening for nalidixic acid resistance with a 30 microg nalidixic acid disk is a reliable and cost-effective method for detection of low-level fluoroquinolone resistance in typhoid salmonellae."
4.	Diarrhea 11/01/1989 - "Efficacy of nalidixic acid in the treatment of acute bloody diarrhea." 08/01/2013 - "Three Yersinia enterocolitica strains cultured from patients presenting with diarrhea and resistant to nalidixic acid were studied. " 08/01/2013 - "Further characterization of three Yersinia enterocolitica strains with a nalidixic acid-resistant phenotype isolated from humans with diarrhea." 04/01/2003 - "Emergence of nalidixic acid-resistant Shigella sonnei in acute-diarrhea patients on Andaman and Nicobar Islands, India." 07/01/2009 - "The aim of the present study was to evaluate the antimicrobial susceptibility of thermophilic Campylobacter strains isolated from patients with diarrhea, as well as from patients with diarrhea followed by postinfections sequels, to drugs used in the therapy of enterocolitis, and to nalidixic acid used in laboratory identification and differentiation of thermophilic Campylobacter spp. We studied the antimicrobial susceptibility profiles of 131 Campylobacter strains isolated from patients with diarrhea (122 strains), diarrhea associated with rheumatic disorders (8 strains), and one strain isolated from a patient with Guillain-Barré Syndrome following Campylobacter enterocolitis. "
5.	Urinary Tract Infections (Urinary Tract Infection) 01/01/2007 - "We determined the possible relationships between the different urinary tract infections, and in vitro biofilm formation, the presence of urovirulence factors and nalidixic acid resistance. " 10/20/1998 - "Nalidixic acid (NA) has been used for urinary tract infections and has been reported to be photocarcinogenic. " 01/01/1998 - "The first qumolone to be clinically used was nalidixic acid, which was used for the treatment of enteric and urinary tract infections. " 10/01/1996 - "Nalidixic acid (NA) is an antimicrobial drug that has been used to treat urinary tract infections. " 07/01/1989 - "Nalidixic acid was the first quinolone developed and was often used in pediatric patients for the treatment of urinary tract infections. "

Related Drugs and Biologics

1.	Ciprofloxacin (Cipro)
2.	Ofloxacin (Levofloxacin)
3.	Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
4.	Oxolinic Acid
5.	Norfloxacin
6.	Pefloxacin
7.	Fluoroquinolones
8.	Azithromycin (Zithromax)
9.	gatifloxacin (Zymar)
10.	Furazolidone (Furoxone)

Related Therapies and Procedures

1.	Oral Administration
2.	Catheters
3.	Drug Therapy (Chemotherapy)
4.	Kidney Transplantation
5.	Long-Term Care